Werewolf to Study WTX-124 With Merck's Keytruda in Solid Tumors
August 18 2021 - 08:45AM
Dow Jones News
By Colin Kellaher
Werewolf Therapeutics Inc. on Wednesday said it formed a
collaboration and supply agreement with Merck & Co. to study
Werewolf's WTX-124 product candidate in combination with Merck's
blockbuster cancer drug Keytruda.
Werewolf, a Cambridge, Mass., biopharmaceutical company, said it
plans to conduct a Phase 1 clinical trial to evaluate the safety
and preliminary efficacy of WTX-124 as a monotherapy and in
combination with Keytruda in patients with solid tumors.
Werewolf said it plans to file for U.S. Food and Drug
Administration approval of the trial in the first half of 2022.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 18, 2021 08:37 ET (12:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2023 to Mar 2024